FI863917A - Förfarande för framställning av farmakologiskt användbara kinazolinderivat - Google Patents

Förfarande för framställning av farmakologiskt användbara kinazolinderivat Download PDF

Info

Publication number
FI863917A
FI863917A FI863917A FI863917A FI863917A FI 863917 A FI863917 A FI 863917A FI 863917 A FI863917 A FI 863917A FI 863917 A FI863917 A FI 863917A FI 863917 A FI863917 A FI 863917A
Authority
FI
Finland
Prior art keywords
method prepares
quinazoline derivatives
alkyl
pharmacologically useful
pharmaceutically acceptable
Prior art date
Application number
FI863917A
Other languages
English (en)
Finnish (fi)
Other versions
FI863917A0 (sv
FI90234B (sv
FI90234C (sv
Inventor
Masashi Hashimoto
Teruo Oku
Yoshikuni Ito
Takayuki Namiki
Kozo Sawada
Chiyoshi Kasahara
Yukihisa Baba
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of FI863917A0 publication Critical patent/FI863917A0/sv
Publication of FI863917A publication Critical patent/FI863917A/sv
Publication of FI90234B publication Critical patent/FI90234B/sv
Application granted granted Critical
Publication of FI90234C publication Critical patent/FI90234C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI863917A 1985-10-07 1986-09-29 Förfarande för framställning av farmakologiskt användbara kinazolinderivat FI90234C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858524663A GB8524663D0 (en) 1985-10-07 1985-10-07 Quinazoline derivatives
GB8524663 1985-10-07

Publications (4)

Publication Number Publication Date
FI863917A0 FI863917A0 (sv) 1986-09-29
FI863917A true FI863917A (sv) 1987-04-08
FI90234B FI90234B (sv) 1993-09-30
FI90234C FI90234C (sv) 1994-01-10

Family

ID=10586291

Family Applications (1)

Application Number Title Priority Date Filing Date
FI863917A FI90234C (sv) 1985-10-07 1986-09-29 Förfarande för framställning av farmakologiskt användbara kinazolinderivat

Country Status (23)

Country Link
US (2) US4734419A (sv)
EP (1) EP0218999B1 (sv)
JP (3) JPS6296476A (sv)
KR (1) KR940007270B1 (sv)
CN (1) CN1017242B (sv)
AT (1) ATE60761T1 (sv)
AU (1) AU596611B2 (sv)
CA (1) CA1289139C (sv)
DE (1) DE3677452D1 (sv)
DK (1) DK158838C (sv)
ES (1) ES2021266B3 (sv)
FI (1) FI90234C (sv)
GB (1) GB8524663D0 (sv)
GR (1) GR3001502T3 (sv)
HK (1) HK6993A (sv)
HU (1) HU196972B (sv)
IE (1) IE59309B1 (sv)
IL (1) IL80213A (sv)
NO (1) NO171785C (sv)
SG (1) SG112092G (sv)
SU (1) SU1588283A3 (sv)
UA (1) UA5562A1 (sv)
ZA (1) ZA867043B (sv)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives
WO1988001270A1 (en) * 1986-08-21 1988-02-25 Pfizer Inc. Pyridopyrimidinediones
US4889851A (en) * 1986-11-21 1989-12-26 Fujisawa Pharmaceutical Co, Ltd. Benzothiadiazine compounds, and pharmaceutical composition comprising the same
US4931440A (en) * 1987-07-29 1990-06-05 Fujisawa Pharmaceutical Company, Ltd. Uricosuric composition
EP0335979A4 (en) * 1987-09-16 1992-02-26 Taiho Pharmaceutical Company, Limited Thienopyrimidine derivatives
JP2621460B2 (ja) * 1988-02-29 1997-06-18 藤沢薬品工業株式会社 利尿または降圧剤
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
CA2229930A1 (en) * 1995-08-31 1997-03-06 Clariant Gmbh Monoesters of carboxymethyleneanthranilic acids and a process for their preparation
DE19532052C2 (de) * 1995-08-31 1998-11-19 Clariant Gmbh Verfahren zur Herstellung von Chinazolinderivaten
EP0781767B1 (en) * 1995-12-26 2001-09-05 Sumitomo Chemical Company, Limited Process for producing isatoic anhydrides
EP0896961A4 (en) 1995-12-28 1999-04-07 Fuji Chem Ind Co Ltd PROCESS FOR THE MANUFACTURE OF 3-DIHALOBENZYL-2,4-QUINAZOLINEDIONE DERIVATIVES
EP0789020B1 (en) * 1996-02-01 2000-04-12 Sumitomo Chemical Company, Limited Process for producing dioxoquinazolines
DE19650975A1 (de) * 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
KR100891756B1 (ko) * 1997-04-15 2009-04-07 씨에스아이알 식욕 억제 활성을 갖는 약학 조성물
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
CN1295476A (zh) 1998-01-30 2001-05-16 株式会社·R-技术上野 眼用组合物
WO2000043015A1 (fr) * 1999-01-25 2000-07-27 Fujisawa Pharmaceutical Co., Ltd. Gouttes ophtalmologiques
JP2003516309A (ja) * 1999-02-18 2003-05-13 株式会社アールテック・ウエノ 涙液分泌障害を除く外分泌障害処置剤
BR0010402A (pt) * 1999-03-09 2002-01-08 Fujisawa Pharmaceutical Co Processo para preparação de derivados de quinazolina
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
GB2396815B (en) * 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
GB2363985B (en) * 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL155710A0 (en) 2000-11-30 2003-11-23 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors
WO2002098462A1 (fr) * 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedes contenant un inhibiteur d'aldose reductase en tant qu'agent actif destines a des troubles de demyelinisation ou des troubles associes a la demyelinisation
AU2003213092A1 (en) * 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
RU2004135554A (ru) * 2002-05-09 2006-01-20 Цитокинетикс, Инк. (Us) Пиримидиноны, композиции на их основе и способы их использования
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003290507A1 (en) * 2002-05-10 2004-04-08 Cytokinetics, Inc. Compounds, compositions and methods
AU2003265242A1 (en) * 2002-05-23 2003-12-22 Cytokinetics, Inc. Compounds, compositions, and methods
EP1556357A4 (en) * 2002-06-14 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004009036A2 (en) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
JP2005536553A (ja) * 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
AU2003277079A1 (en) * 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005041888A2 (en) * 2003-11-03 2005-05-12 Cytokinetics, Inc. Pyrimidin-4-one compounds, compositions and methods
EP1680420A4 (en) * 2003-11-07 2008-09-24 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
JP2007513154A (ja) * 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
VN28357A1 (en) * 2006-07-19 2011-12-26 Du Pont Process for making 3-substituted 2-amino-5-halobenzamides
ATE518544T1 (de) 2007-03-12 2011-08-15 Zadec Aps Rotbusch-extrakt gegen diabetes
WO2008118844A1 (en) 2007-03-23 2008-10-02 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
WO2009019149A1 (en) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
CN102219759B (zh) * 2010-04-16 2013-07-24 中国科学院上海药物研究所 芳基甲酰胺类化合物及其制备方法、药物组合物和用途
CA2822672C (en) 2010-12-23 2018-06-05 The Board Of Regents Of The University Of Texas System Methods for treating copd
EA030942B1 (ru) 2013-05-10 2018-10-31 Джилид Аполло, Ллс Ингибиторы акк и их применение
JP6417401B2 (ja) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
BR112015028214A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
CN111499616B (zh) * 2020-05-07 2022-07-22 盐城工学院 一种芳杂环取代的喹唑啉酮衍生物及其合成方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1491510A (en) * 1973-12-14 1977-11-09 Hisamitsu Pharmaceutical Co 1-nitrophenylquinazoline-2,4(1h,3h)-diones
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
CA1161036A (en) * 1980-05-15 1984-01-24 Masayuki Ishikawa Quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
EP0040793B1 (en) * 1980-05-22 1985-08-28 Masayuki Ishikawa Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
JPS58159480A (ja) * 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
DD232702A1 (de) * 1982-09-20 1986-02-05 Adw Ddr Verfahren zur herstellung von 1,2,3,4-tetrahydrochinazolin-2,4-dion-essigsaeuren, deren salzen und estern
US4490374A (en) * 1982-09-30 1984-12-25 Ortho Pharmaceutical Corporation 5,6-Dialkoxy-3,4-optionally substituted-2(1H)quinazolinones, composition and method of use
JPS59186963A (ja) * 1983-04-08 1984-10-23 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
GB8524663D0 (en) * 1985-10-07 1985-11-13 Fujisawa Pharmaceutical Co Quinazoline derivatives

Also Published As

Publication number Publication date
JPH0794447B2 (ja) 1995-10-11
US4883800A (en) 1989-11-28
NO171785C (no) 1993-05-05
JPH01125322A (ja) 1989-05-17
SG112092G (en) 1992-12-24
DE3677452D1 (de) 1991-03-14
JPH0482148B2 (sv) 1992-12-25
HU196972B (en) 1989-02-28
GB8524663D0 (en) 1985-11-13
KR870003998A (ko) 1987-05-06
IE862520L (en) 1987-04-07
UA5562A1 (uk) 1994-12-28
FI863917A0 (sv) 1986-09-29
JPS6296476A (ja) 1987-05-02
FI90234B (sv) 1993-09-30
AU596611B2 (en) 1990-05-10
CN1017242B (zh) 1992-07-01
IL80213A0 (en) 1987-01-30
EP0218999A2 (en) 1987-04-22
US4734419A (en) 1988-03-29
DK158838C (da) 1991-01-14
GR3001502T3 (en) 1992-11-23
ZA867043B (en) 1987-07-29
HK6993A (en) 1993-02-05
JPH01131164A (ja) 1989-05-24
AU6358986A (en) 1987-04-09
IE59309B1 (en) 1994-02-09
DK459086D0 (da) 1986-09-25
EP0218999A3 (en) 1988-01-13
JPH05366B2 (sv) 1993-01-05
HUT41747A (en) 1987-05-28
NO863980D0 (no) 1986-10-06
SU1588283A3 (ru) 1990-08-23
CA1289139C (en) 1991-09-17
ATE60761T1 (de) 1991-02-15
EP0218999B1 (en) 1991-02-06
CN86106984A (zh) 1987-05-20
FI90234C (sv) 1994-01-10
KR940007270B1 (en) 1994-08-12
NO171785B (no) 1993-01-25
NO863980L (no) 1987-04-08
IL80213A (en) 1991-06-30
DK158838B (da) 1990-07-23
ES2021266B3 (es) 1991-11-01
DK459086A (da) 1987-04-08

Similar Documents

Publication Publication Date Title
FI863917A (sv) Förfarande för framställning av farmakologiskt användbara kinazolinderivat
MX9306831A (es) Nuevos compuestos heterociclicos.
DE69431974D1 (de) Benzamid-Derivate und ihre Verwendung als Vasopressin-Antagonisten
DK0622361T3 (da) Heterocykliske forbindelser som bradykininantagonister
NO903438L (no) Fremgangsmaate for fremstilling av tiazolderivater.
FI862757A (fi) Pyridonkarbonsyraderivat och foerfarande foer framstaellning av dessa.
ATE126796T1 (de) Quinazolinderivate und ihre herstellung.
DK283984D0 (da) Benzodiazepinderivater og fremgangsmaade til fremstilling deraf
DE68927286D1 (de) Pyrrolidin-Derivate
FI893570A0 (sv) Förfarande för framställning av som läkemedel användbara derivat av 1H-imidazo/1,2-b/pyrazol
DK210387A (da) Heterocykliske forbindelser og fremgangsmaade til deres fremstilling samt farmaceutiske midler indeholdende disse

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: FUJISAWA PHARMACEUTICAL CO., LTD.